<b>Gapping up <br/>In reaction to strong earnings/guidance:</b><br/>APOP +25.4%, CAPR +18.6%, AKAM +8.5%, MDCO +8.1%, IRBT +5.6%, USNA +4.5%, WBA +4.4%, MKSI +4.3%, KRA +4.1%, LPL +4.1%, RES +3.5%, RGC +3.4%, BTI +3.1%, (provides update to outlook at its Capital Markets Day), TUP +3%, NOC +2.9%, TSS +2.7%, OFG +2.5%, FLIR +2.5%, AMED +2.4%, WB +2.3%, (also commences $700 mln offering of convertible senior notes due 2022 ), ILMN +2%, COF +1.9%, LYG +1.7%, HES +1.7%, SIX +1.5%, VNOM +1.4%, BXMT +1.4%, SIRI +1.4%, AVY +1.1%, CNI +1%, NUVA +1%, CEO +0.8%, AOS +0.8%, BAX +0.6%<br/><b>M&A news:</b><br/>S +1.4% (T-Mobile US and Sprint (S) are preparing Boards for merger decision, according to Reuters)<br/><b>Other news:</b><br/>BONT +21.2% (after closing near highs on credit facility update)<br/>OSTK +4.4% (extending today's move higher after confirming key details on tZERO's ICO at Money 20/20 )<br/>LL +4.4% (disclosed memorandum of understanding to settle class actions related to Chinese-Laminate flooring )<br/>SENS +3.3% (continued strength)<br/>ANTM +2.8% (announces that the Co has successfully activated fifteen clinical trial sites in the pivotal Phase 3 SIERRA trial for Iomab-B)<br/>MZOR +2.3% (reports 379-Patient controlled study also reveals seven-fold reduction in revision surgery)<br/>AMC +1.4% (following RGC results)<br/>TNDM +1.1% (to make any new features approved for the t:slim X2 Insulin Pump by the FDA in 2018 available to all in-warranty users at no cost through the Tandem Device Updater )<br/>VRAY +0.9% (raised approx $50 mln through offering)<br/><b>Analyst comments:</b><br/>ALDX +4.8% (initiated with a Overweight at Cantor Fitzgerald)<br/>LDOS +1.4% (upgraded to Outperform from Market Perform at Wells Fargo)<br/>UAL +1% (upgraded to Outperform at Evercore ISI)<br/><b>Gapping down<br/>In reaction to disappointing earnings/guidance:</b><br/>ACHC -22.3%, AMD -10.7%, CMG -10.6%, MANH -9.9%, GHM -8.5%, JNPR -6.7%, EW -6.3%, VICR -6.3%, DPS -5.1%, SFLY -3.6%, NBR -3.4%, EXP -3.3%, DFS -3.1%, WYN -2.3%, AMX -2.1%, T -2%, TXN -1.7%, OC -1.6%, ESRX -1.4%, ROL -1.1%<br/><b>Other news:</b><br/>SNSS -13.5% (commences offering of common stock and Series D Convertible Preferred Stock)<br/>SVRA -11% (commences common stock offering; size not disclosed; anounces its indication expansion strategy of its lead product candidate Molgradex for the treatment of nontuberculous mycobacterial lung infection; plans to initiate a Phase 2a multi-center clinical trial in subjects with antibiotic-resistant NTM lung infection in early 2018)<br/>HCM -9.4% (to offer $262.0 million of ADS's, each representing one-half of one ordinary share )<br/>IDRA -8.7% ( commences $60 mln common stock offering)<br/>SALT -7.8% (commences 10 mln common stock offering )<br/>BIOA -6.5% (accepted the resignation of Pres/COO Fabrice Orecchioni; will be assuming advisory role through to February 24, 2018)<br/>SACH -6% (prices 3.75 mln common stock offering at $4.00/share)<br/>PFLT -4.5% (to make a public offering of 6,000,000 shares of its common stock )<br/>ATNM -4.1% ( indicated lower after filing for $200 mln mixed securities shelf offering and $75 mln ATM under 424B3)<br/>IMDZ -1.1% (prices 18.5 mln shares of common stock at $4.10 per share)<br/>NVDA -0.5% (following AMD results)<br/><b>Analyst comments:</b><br/>RCII -5.3% (downgraded to Market Perform from Outperform at BMO Capital Markets)<br/>PII -1.7% (downgraded to Market Perform from Outperform at BMO Capital Markets)<br/>GM -1.7% (downgraded to Equal-Weight from Overweight at Morgan Stanley)<br/>HBI -1% (downgraded to Market Perform from Outperform at Wells Fargo)<br/>NVS -0.5% (downgraded to Underweight from Equal Weight at Barclays)<br/><br/>Briefing.com